Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Protagonist Therapeutics (PTGX)

Protagonist Q4 net income rises to $131.7 million, helped by $165.0 million milestone

Positive Impact 3 of 5 earnings Written later

Protagonist Therapeutics reported fourth-quarter and full-year 2024 results. Net income was $131.7 million, or $2.11 per basic share, in the fourth quarter, up from $27.3 million a year earlier, and $275.2 million for 2024, compared with a net loss of $79.0 million in 2023. The company said its cash position, including a $165.0 million milestone payment received in January 2025, should fund operations through at least the end of 2028.

Key points

  • Q4 2024 license and collaboration revenue was $170.6 million, versus $60.0 million in Q4 2023.
  • Full-year 2024 license and collaboration revenue was $434.4 million, versus $60.0 million in 2023, mainly from the Takeda agreement and the JNJ milestones.
  • Cash, cash equivalents and marketable securities were $559.2 million as of December 31, 2024, compared with $341.6 million a year earlier.
  • Topline results from the Phase 3 VERIFY rusfertide trial and the Phase 2b ANTHEM icotrokinra trial are expected in March 2025.

The filing

CompanyProtagonist Therapeutics (PTGX)
Form8-K, current report
Filed with the SECFeb 21, 2025, 7:07 AM ET
Accession number0001104659-25-015897

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:17 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 21, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.